marstacimab
Jump to navigation
Jump to search
Indications
- investigational agent for prevention of bleeding in patients with hemophilia A & hemophilia B without inhibitors[1]
Dosage
Mechanism of action
- marstacimab targets the tissue factor pathway inhibitor
More general terms
References
- ↑ 1.0 1.1 Melville NA Hemophilia: Marstacimab Sustains Long-Term Bleeding Decrease. Medscape. June 28, 2024 https://www.medscape.com/s/viewarticle/hemophilia-marstacimab-sustains-long-term-bleeding-decrease-2024a1000c2a